KARUS THERAPEUTICS LTD has a total of 227 patent applications. It decreased the IP activity by 31.0%. Its first patent ever was published in 2006. It filed its patents most often in United Kingdom, WIPO (World Intellectual Property Organization) and United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are BEIJING SCITECH MQ PHARMACEUTICALS LTD, VERNALIS (R&D) LTD and TRANSTECH PHARMA LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 48 | |
#2 | WIPO (World Intellectual Property Organization) | 25 | |
#3 | United States | 23 | |
#4 | EPO (European Patent Office) | 22 | |
#5 | China | 20 | |
#6 | Canada | 15 | |
#7 | Australia | 13 | |
#8 | Mexico | 13 | |
#9 | Israel | 10 | |
#10 | Republic of Korea | 7 | |
#11 | Brazil | 5 | |
#12 | Singapore | 5 | |
#13 | Hong Kong | 4 | |
#14 | New Zealand | 4 | |
#15 | India | 3 | |
#16 | Japan | 3 | |
#17 | South Africa | 3 | |
#18 | Hungary | 2 | |
#19 | Serbia | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Environmental technology | |
#5 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds | |
#4 | Peptides | |
#5 | Climate change mitigation in goods production | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Shuttleworth Stephen Joseph | 134 |
#2 | Silva Franck Alexandre | 98 |
#3 | Cecil Alexander Richard Liam | 94 |
#4 | Tomassi Cyrille Davy | 51 |
#5 | Maccormick Somhairle | 37 |
#6 | Nodes William John | 33 |
#7 | Whale Andrew David | 27 |
#8 | Hill Thomas James | 23 |
#9 | Stephen Joseph Shuttleworth | 18 |
#10 | Gatland Alice Elizabeth | 15 |
Publication | Filing date | Title |
---|---|---|
GB202009784D0 | Histone deacetylase inhibitors | |
GB201912813D0 | Histone deacetylase inhibitors | |
GB201909466D0 | Compounds for treating cancer | |
GB201909468D0 | Compounds for treating cancer | |
GB201907955D0 | Histone deacetylase inhibitors | |
GB201803361D0 | Histone deacetylase inhibitors | |
GB201609786D0 | Compounds and method of use | |
GB201514751D0 | Compounds | |
GB201514754D0 | Compounds | |
GB201514756D0 | Compound and method of use | |
GB201514758D0 | Formulation | |
GB201514760D0 | Compounds and method of use | |
GB201514770D0 | Compounds and their use | |
GB201419228D0 | Compounds | |
GB201419264D0 | Compounds | |
GB201416116D0 | Compounds | |
CN105358550A | Novel histone deacetylase inhibitors | |
GB201402431D0 | Compounds | |
NZ707366A | Novel histone deacetylase inhibitors and their use in therapy | |
GB201315254D0 | Compounds |